What is LeonaBio, Inc.'s market cap?

LeonaBio, Inc. (LONA) has a market capitalization of $73.6M and trades on NASDAQ.

Who are LeonaBio, Inc.'s competitors?

LeonaBio, Inc.'s key competitors include Eli Lilly, Arvinas, Olema Pharmaceuticals, and others. These companies compete in similar markets and product categories.

Who does LeonaBio, Inc. partner with?

LeonaBio, Inc.'s notable partners include Sermonix Pharmaceuticals, Inc., Ligand Pharmaceuticals, Pfizer Inc., and others.

Where is LeonaBio, Inc. headquartered?

LeonaBio, Inc. is headquartered in United States of America. It has been publicly traded since 2020.

LeonaBio, Inc. (LONA) Stock Fundamentals & Financials

LeonaBio is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for high unmet medical needs in oncology and neurology.

Market cap

$73.58M+64.5%

Net income-$129.4M-62.3%

EPS (diluted)-$22.49-56.6%

Trailing twelve months · change vs. prior year

Earnings

Q2 2026 report

August 14, 2026

EPS-$0.80Beat by $0.59

Read the full report

Next report

Nov 5, 2026 (in 2 months)

EPS estimate-$0.69

Financials

Q1 2026

Income statement

See full

Operating income-$17.2M-80.5%

Net income-$32.9M-260%

EPS (diluted)-$1.73+26.1%

Balance sheet

See full

Cash & equivalents$32.8M+24.3%

Total debt$691.0K-38.2%

Total equity$49.3M+32.1%

Total assets$71.6M+64.5%

Cash flow

See full

Operating cash flow-$20.9M-42.5%

Valuation & ratios

Valuation

See full

Market cap$73.58M+64.5%

Enterprise value$41.44M—

Returns & leverage

See full

Return on equity-298.8%-726pp

Debt / equity0×0.0×

Current ratio10.4×+3.1×

Competitors

By market cap

Eli Lilly$1.06T+61.1%

Erasca, Inc.$6.7B+1,394%

Olema Pharmaceuticals, Inc.$949.3M+141%

Aura Biosciences, Inc.$801.6M+100%

Arvinas$609.4M+2.7%

Zentalis Pharmaceuticals, Inc.$368.3M+181%

LON

LeonaBio, Inc.$73.6M—

Atossa Therapeutics, Inc.$26.4M-73.1%

By revenue growth

Eli Lilly+49.6%

Arvinas-79.1%

By net margin

Eli Lilly33.53%+7.6pp

Arvinas-247.54%-237pp

Profile

LeonaBio is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for high unmet medical needs in oncology and neurology. The company's core value proposition lies in advancing late-stage assets that target treatment-resistant metastatic breast cancer and neurodegenerative diseases like ALS through differentiated mechanisms of action.

Competitive position

LeonaBio is a clinical-stage developer leveraging a unique multimodal mechanism for neurodegeneration and a late-stage, in-licensed oncology asset with established safety data.

GeographiesUnited States, Europe, Global

Customer segmentsPatients, Healthcare providers, Pharmaceutical partners

Business modelR&D intensive, IP licensing, Clinical-stage drug development

SuppliersContract Development and Manufacturing Organizations (CDMOs), Clinical Research Organizations (CROs), Academic research institutions, IP licensors

CustomersSpecialty pharmacies, Hospitals, Oncology and Neurology clinics, Pharmaceutical distributors

CountryUnited States of America

Listed2020

CEOMark J. Litton

SectorHealthcare

IndustryBiotechnology

Websiteleonabio.com

FilingsSEC EDGAR

FAQ

What is LeonaBio, Inc.'s market cap?: LeonaBio, Inc. (LONA) has a market capitalization of $73.6M and trades on NASDAQ.
Who are LeonaBio, Inc.'s competitors?: LeonaBio, Inc.'s key competitors include Eli Lilly, Arvinas, Olema Pharmaceuticals, and others. These companies compete in similar markets and product categories.
Who does LeonaBio, Inc. partner with?: LeonaBio, Inc.'s notable partners include Sermonix Pharmaceuticals, Inc., Ligand Pharmaceuticals, Pfizer Inc., and others.
Where is LeonaBio, Inc. headquartered?: LeonaBio, Inc. is headquartered in United States of America. It has been publicly traded since 2020.